Meeting Banner
Abstract #2720

Vascular Response of Hepatocellular Carcinoma to Pazopanib Measured by Dynamic Contrast-Enhanced MRI: Pharmacokinetic and Clinical Activity Correlations

Philip Stephen Murphy1, Caleb Roberts2, Brandon Whitcher3, Frank Stornanti4, Jennifer Gauvin5, Thomas Yau6, Pei-Jer Chen7, Martin Curtis5, Ben Suttle5, Thangam Arumugham5, Jeffrey Hodge5, Mohammed Dar5, Ronnie Poon6, Geoff JM Parker2

1Oncology Clinical R&D, GlaxoSmithKline, Uxbridge, Middlesex, United Kingdom; 2Imaging Science and Biomedical Engineering, School of Cancer and Imaging Sciences, University of Manchester, Manchester, United Kingdom; 3Clinical Imaging Centre, GlaxoSmithKline, London, United Kingdom; 4Perceptive Informatics, Billerica, United States; 5Oncology Research, GlaxoSmithKline, Research Triangle Park, United States; 6Queen Mary Hospital, Hong Kong, China; 7National Taiwan University Hospital, Taipei, Taiwan

When performing dynamic contrast enhanced MRI (DCE-MRI) in the dose-ranging setting, correlating the readout to individual pharmacokinetic (PK) parameters is more informative than relating to dose alone. In a study of the VEGF receptor inhibitor pazopanib in hepatocellular carcinoma (HCC), relationships between image-based measures of vascular function, PK parameters, and clinical activity were observed.